Table 1. Baseline and pre-treatment patient characteristics.
| Characteristics | Values (n=49) |
|---|---|
| Age (years), median [range] | 64 [39–82] |
| Sex, n (%) | |
| Male | 26 (53.1) |
| Female | 23 (46.9) |
| Tumor histology, n (%) | |
| Adenocarcinoma | 47 (95.9) |
| Squamous cell carcinoma | 2 (4.1) |
| Prior treatment, n (%) | |
| First generation TKI | 9 (18.4) |
| Chemotherapy | 4 (8.2) |
| EBRT | 6 (12.2) |
| SRS | 9 (18.4) |
| Oligometastatic disease type, n (%) | |
| Oligoprogressive | 32 (65.3) |
| Oligopersistent | 17 (34.7) |
| EGFR, n (%) | |
| Ex.19 Del | 16 (32.7) |
| Ex.21L858R | 9 (18.4) |
| Ex.19 Point M | 1 (2.0) |
| Ex.21 Point M | 1 (2.0) |
| Ex.18/Ex.20 | 2 (4.1) |
| Wild type | 20 (40.8) |
| PD-L1, n (%) | |
| <1% | 4 (8.2) |
| 1–50% | 5 (10.2) |
| >50% | 13 (26.5) |
TKI, tyrosine kinase inhibitor; EBRT, external beam radiation therapy; SRS, stereotactic radiosurgery; EGFR, epidermal growth factor receptor; PD-L1, programmed cell death-ligand 1.